文献速递传染病防控与疫情报告卫生政策与健康促进

爱尔兰居民COVID-19感染研究(SCOPI):2020年6月至7月的血清流行率研究

The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020.
PubMed 文献 · Euro Surveill · 2021-01-01

该研究采用横断面设计,从都柏林和斯莱戈两郡12-69岁人群中抽样,用Abbott Architect SARS-CoV-2 IgG检测并Wantai确认抗体,按年龄、性别和地区加权估计血清流行率。都柏林加权血清流行率为3.12%(95%CI:2.05-4.53),斯莱戈为0.58%(95%CI:0.18-1.38),全国为1.69%(95%CI:1.13-2.41),估计全国有59,482人(95%CI:39,772-85,176)曾感染,是确诊病例数的3.0倍(95%CI:2.0-4.3)。结论认为2020年6-7月爱尔兰多数人可能未感染,非药物公共卫生措施在疫苗广泛可用前仍关键。

要点

  • 全国加权SARS-CoV-2血清流行率为1.69%(95%CI:1.13-2.41)。
  • 估计感染人数59,482(95%CI:39,772-85,176),为确诊病例的3.0倍(95%CI:2.0-4.3)。
  • 33份标本抗体阳性(1.9%),其中25人未报告既往实验室确诊感染。

核心结论

  • 2020年6-7月爱尔兰多数人可能未感染SARS-CoV-2;在疫苗广泛可用前,非药物公共卫生措施仍关键。

研究设计与样本

  • 横断面研究,从都柏林和斯莱戈两郡12-69岁人群中,以Health Service Executive Primary Care Reimbursement Service数据库为抽样框,按年龄-性别分布概率比例抽样并在层内简单随机抽样。
  • 使用Abbott Architect SARS-CoV-2 IgG Assay检测抗体并用Wantai Assay确认,按年龄、性别和地理区域加权估计血清流行率。

主要发现

  • 都柏林参与率30%(913/3,043),斯莱戈参与率44%(820/1,863)。
  • 33份标本可检出SARS-CoV-2抗体(1.9%)。
  • 加权血清流行率:都柏林3.12%(95%CI:2.05-4.53),斯莱戈0.58%(95%CI:0.18-1.38),全国1.69%(95%CI:1.13-2.41)。
  • 估计全国12-69岁人群中有59,482人(95%CI:39,772-85,176)曾感染SARS-CoV-2,是确诊病例数的3.0倍(95%CI:2.0-4.3)。
  • 10名参与者报告既往实验室确诊SARS-CoV-2感染,其中8人抗体阳性;25名抗体阳性参与者未报告既往实验室确诊感染。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundRobust data on SARS-CoV-2 population seroprevalence supplement surveillance data in providing evidence for public health action.AimTo conduct a SARS-CoV-2 population-based seroprevalence survey in Ireland.MethodsUsing a cross-sectional study design, we selected population samples from individuals aged 12-69 years in counties Dublin and Sligo using the Health Service Executive Primary Care Reimbursement Service database as a sampling frame. Samples were selected with probability proportional to the general population age-sex distribution, and by simple random sampling within age-sex strata. Antibodies to SARS-CoV-2 were detected using the Abbott Architect SARS-CoV-2 IgG Assay and confirmed using the Wantai Assay. We estimated the population SARS-CoV-2 seroprevalence weighted for age, sex and geographic area.ResultsParticipation rates were 30% (913/3,043) and 44% (820/1,863) in Dublin and Sligo. Thirty-three specimens had detectable SARS-CoV-2 antibodies (1.9%). We estimated weighted seroprevalences of 3.12% (95% confidence interval (CI): 2.05-4.53) and 0.58% (95% CI: 0.18-1.38) for Dublin and Sligo, and 1.69% (95% CI: 1.13-2.41) nationally. This equates to an estimated 59,482 (95% CI: 39,772-85,176) people aged 12-69 years nationally having had infection with SARS-CoV-2, 3.0 (95% CI: 2.0-4.3) times higher than confirmed notifications. Ten participants reported a previous laboratory-confirmed SARS-CoV-2 -infection; eight of these were antibody-positive. Twenty-five antibody-positive participants had not reported previous laboratory-confirmed infection.ConclusionThe majority of people in Ireland are unlikely to have been infected with SARS-CoV-2 by June-July 2020. Non-pharmaceutical public health measures remained key pending widespread availability of vaccination, and effective treatments.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Heavey L, Garvey P, Colgan AM, et al. The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020. Euro Surveill. 2021. PMID: 34857067. doi:10.2807/1560-7917.ES.2021.26.48.2001741

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。